Cabozantinib Atezolizumab PFS mCRPC Metastases
Cabozantinib Plus Atezolizumab Shows promise in Metastatic Castration-Resistant Prostate Cancer, improving Progression-Free Survival
Table of Contents
A important advancement in the treatment of metastatic castration-resistant prostate cancer (mCRPC) has emerged from the CONTACT-02 trial, revealing that the combination of cabozantinib and atezolizumab substantially improved progression-free survival (PFS) compared to androgen receptor pathway inhibitors (ARPIs) alone. While overall survival (OS) did not show a statistically significant difference,the findings represent a crucial step forward,marking the first phase 3 trial to demonstrate a PFS benefit with a tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) combination in this challenging patient population.
Efficacy outcomes: A Closer Look at the Data
The CONTACT-02 trial, a phase 3, open-label, randomized study, followed patients for a median of 11.8 months. The results presented are compelling:
Progression-Free Survival (PFS): Patients treated with cabozantinib and atezolizumab experienced a median PFS of 6.3 months (95% CI, 6.2-8.8). This stands in stark contrast to the 4.2 months median PFS observed in the ARPI arm (95% CI, 3.7-5.7). The hazard ratio (HR) of 0.65 (95% CI, 0.50-0.84) indicates a statistically significant advancement (P =.0007). This means patients on the combination therapy were less likely to experience disease progression.
Objective Response rate (ORR): The experimental combination demonstrated a higher ORR, with 13% of patients responding compared to 6% in the ARPI arm.
tumor Shrinkage: A notable 68% of patients in the cabozantinib-atezolizumab group experienced tumor shrinkage, a significant increase from the 37% seen in the ARPI arm.
Disease Control: The disease control rate (DCR) also favored the combination, with 72% of patients achieving disease control versus 53% in the ARPI arm.
* Progressive Disease: encouragingly, fewer patients in the combination arm exhibited progressive disease as their best response (17% vs. 31%).
However, it’s significant to note that the final analysis of overall survival (OS) did not reveal a statistically significant difference between the two arms. The median OS was 14.8 months for the cabozantinib-atezolizumab group and 15.0 months for the ARPI arm (HR, 0.89; 95% CI, 0.72-1.10; P =.30).
Safety Profile: Understanding the Side effects
As is often the case with combination therapies, the cabozantinib-atezolizumab regimen was associated with a higher incidence of treatment-related adverse events (TRAEs). Specifically, 40% of patients in the experimental arm experienced grade 3/4 events, compared to 8% in the ARPI arm.
The most common high-grade toxicities observed in the cabozantinib-atezolizumab group were hypertension (8%) and anemia (8%). In the control group, anemia (6%) was the predominant high-grade toxicity. The median duration of treatment was 6.3 months (IQR, 3.4-11.0) for the combination therapy and 4.2 months (IQR, 2.1-9.0) for ARPIs. The safety profile observed in CONTACT-02 aligns with previous data for this combination.
Context and Future Directions
The CONTACT-02 trial’s findings are especially noteworthy when contrasted with other studies. The negative IMbassador250 trial,as a notable example,found that atezolizumab plus enzalutamide did not improve outcomes in an unselected mCRPC population,even though a PFS benefit was observed in subgroups with high PD-L1 expression. This highlights the potential for specific combinations and patient selection to yield different results.